产品名称	ACT-1人甲状腺癌细胞
货号	ZQ0310
产品介绍	人甲状腺未分化癌细胞（anaplastic thyroid carcinoma, ATC）；该细胞株经过STR鉴定，与国际上ATCC、DSMZ、JCRB和RIKEN 公布的STR数据库中8000余种细胞均不相符，排除被常见细胞系污染的可能。由于ACT-1细胞本身没有公布可比对的STR图谱数据，我们只能初步判断该细胞可能为ACT-1。
种属	人
性别/年龄	不详
组织	甲状腺
疾病	甲状腺未分化癌
细胞类型	肿瘤细胞
形态学	上皮细胞
生长方式	贴壁
倍增时间	大约48~72小时
培养基和添加剂	DMEM (中乔新舟  货号：ZQ-100)+10%胎牛血清（中乔新舟  货号：ZQ500-A）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM0310
生物安全等级	BSL-1
STR位点信息	D5S818: 11,13；D13S317: 10,12；D7S820: 10,11；D16S539: 9,11；vWA: 17,18；THO1: 6,9；Amelogenin: X；TPOX: 8；CSF1PO: 11,12
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达
基因表达
保藏机构	cancercelllines;
供应限制	仅供科研使用

货号	ZQ0310
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

论文标题： LncRNA PVT1 Acts as a Tumor Promoter in Thyroid Cancer and Promotes Tumor Progression by Mediating miR-423-5p-PAK3
DOI： 10.2147/CMAR.S283443
发表时间： 2020-12-30
期刊： Cancer Management and Research
影响因子： 2.886
货号： ZQ0310
产品名称： ACT-1 cells

原文链接： https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779291/

PubMed=12495476; DOI=10.1111/j.1349-7006.2002.tb01245.x
Chung S.-H., Onoda N., Ishikawa T., Ogisawa K., Takenaka C., Yano Y., Hato F., Hirakawa K.
Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells.
Jpn. J. Cancer Res. 93:1358-1365(2002)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=26137260; DOI=10.3892/mco.2015.496
Onoda N., Nakamura M., Aomatsu N., Noda S., Kashiwagi S., Kurata K., Uchino S., Hirakawa K.
Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.
Mol. Clin. Oncol. 3:522-526(2015)

PubMed=26680454; DOI=10.1186/s12885-015-1955-9
Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y.-J., Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.
The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
BMC Cancer 15:984.1-984.11(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)